PT - JOURNAL ARTICLE AU - Ciavarella, Anthony AU - Khan, Mansoor AU - Gupta, Abhay AU - Faustino, Patrick TI - Dose uniformity of scored and unscored tablets: Application of the FDA Tablet Scoring Guidance for Industry AID - 10.5731/pdajpst.2015.006411 DP - 2016 Jan 01 TA - PDA Journal of Pharmaceutical Science and Technology PG - pdajpst.2015.006411 4099 - http://journal.pda.org/content/early/2016/06/18/pdajpst.2015.006411.short 4100 - http://journal.pda.org/content/early/2016/06/18/pdajpst.2015.006411.full AB - Purpose: This FDA laboratory study examines the impact of tablet splitting, the effect of tablet splitters, and the presence of a tablet score on the dose uniformity of two model drugs. Methods: Whole tablets were purchased from five manufacturers for amlodipine and six for gabapentin. Two splitters were used for each drug product and the gabapentin tablets were also split by hand. Whole and split amlodipine tablets were tested for content uniformity following the general chapter of the United States Pharmacopeia (USP) Uniformity of Dosage Units <905>, which is a requirement of the new FDA Guidance for Industry on tablet scoring. The USP weight variation method was used for gabapentin split tablets based on the recommendation of the guidance. Results: All whole tablets met the USP acceptance criteria for the Uniformity of Dosage Units. Variation in whole tablet content ranged from 0.5-2.1 standard deviation (SD) of the % label claim. Splitting the unscored amlodipine tablets resulted in a significant increase in dose variability of 6.5-25.4 SD when compared to whole tablets. Split tablets from all amlodipine drug products did not meet the USP acceptance criteria for content uniformity. Variation in the weight for gabapentin split tablets was greater than the whole tablets, ranging from 1.3-9.3 SD. All fully scored gabapentin products met the USP acceptance criteria for weight variation. Conclusion: Size, shape, and the presence or absence of a tablet score can affect the content uniformity and weight variation of amlodipine and gabapentin tablets. Tablet splitting produced higher variability. Differences in dose variability and fragmentation were observed between tablet splitters and hand splitting. These results are consistent with the FDA's concerns that tablet splitting "can affect how much drug is present in the split tablet and available for absorption" as stated in the guidance (1).